Successful financing round for pharmaceutical companies AMW
AMW GmbH (Arzneimittelwerk Warngau) has received follow-up funding to advance the development and marketing process for its drug delivery systems. The old investors together with BayBG Bayerische Beteiligungsgesellschaft, the UnternehmerTUM-Fonds and the IBG Beteiligungsgesellschaft are depositing a total of up to seven million euros. The funds will be used to market the existing product portfolio and to develop a new technology for the controlled supply of medicinal products. AMW GmbH produces active ingredient implants as well as transdermal systems in the high-growth areas of oncology, pain therapy and neurology.
read more